GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tango Therapeutics Inc (NAS:TNGX) » Definitions » Interest Coverage

Tango Therapeutics (Tango Therapeutics) Interest Coverage : N/A (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tango Therapeutics Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Tango Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-42.26 Mil. Tango Therapeutics's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Tango Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

The historical rank and industry rank for Tango Therapeutics's Interest Coverage or its related term are showing as below:


TNGX's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 145.09
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Tango Therapeutics Interest Coverage Historical Data

The historical data trend for Tango Therapeutics's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tango Therapeutics Interest Coverage Chart

Tango Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Interest Coverage
N/A No Debt N/A N/A

Tango Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Tango Therapeutics's Interest Coverage

For the Biotechnology subindustry, Tango Therapeutics's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tango Therapeutics's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tango Therapeutics's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Tango Therapeutics's Interest Coverage falls into.



Tango Therapeutics Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Tango Therapeutics's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Tango Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-114.17 Mil. And its Long-Term Debt & Capital Lease Obligation was $36.84 Mil.

GuruFocus does not calculate Tango Therapeutics's interest coverage with the available data.

Tango Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, Tango Therapeutics's Interest Expense was $0.00 Mil. Its Operating Income was $-42.26 Mil. And its Long-Term Debt & Capital Lease Obligation was $36.17 Mil.

GuruFocus does not calculate Tango Therapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Tango Therapeutics  (NAS:TNGX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Tango Therapeutics Interest Coverage Related Terms

Thank you for viewing the detailed overview of Tango Therapeutics's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Tango Therapeutics (Tango Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
201 Brookline Avenue, Suite 901, Boston, MA, USA, 02215
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies.
Executives
Adam Crystal officer: See Remarks C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN MA 02472
Boxer Capital, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
John B Ketchum director TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Joseph Lewis other: See remarks PO BOX N7776, LYFORD BAHAMAS
Trv Gp Vi, Llc director 201 BROOKLINE AVE., BOSTON MA 02215
Third Rock Ventures Gp Vi, L.p. director 201 BROOKLINE AVE, SUITE 1401, BOSTON MA 02215
Third Rock Ventures Vi, L.p. director 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Aaron I. Davis other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Boxer Asset Management Inc. other: See remarks CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Mva Investors, Llc other: See remarks 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron Weitzman officer: Chief Medical Officer TANGO THERAPEUTICS, INC., 201 BROOKLINE AVE., SUITE 901, BOSTON MA 02215
Marc Rudoltz officer: Chief Medical Officer TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Douglas Barry officer: See Remarks TANGO THERAPEUTICS, INC., 100 BINNEY STREET, UNIT 700, CAMBRIDGE MA 02142
Third Rock Ventures Iv, L.p. 10 percent owner 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116

Tango Therapeutics (Tango Therapeutics) Headlines

From GuruFocus